Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 13 years
- Director since
- 2023
13 years of board service in total across 4 boards, counting each seat separately. Longest: Cytokinetics Incorporated, 3 years.
Cytokinetics Incorporated
Director
Veracyte Inc.
Director
Ardelyx Inc.
Director
Intellia Therapeutics Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cytokinetics Incorporated May 14, 202587.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 1, 2026 | Veracyte Inc. | Open-market sale | −1,864 | $42.97 | $80,096 |
| Jun 16, 2026 | Ardelyx Inc. | Grant or award | +26,455 | — | — |
| Jun 11, 2026 | Veracyte Inc. | Grant or award | +5,272 | — | — |
| Jun 9, 2026 | Intellia Therapeutics Inc. | Grant or award | +9,200 | — | — |
| May 27, 2026 | Cytokinetics Incorporated | Grant or award | +2,851 | — | — |
| Jun 18, 2025 | Ardelyx Inc. | Grant or award | +41,551 | — | — |
| Jun 18, 2025 | Veracyte Inc. | Grant or award | +9,321 | — | — |
| Jun 13, 2025 | Veracyte Inc. | Open-market sale | −4,589 | $26.67 | $122,389 |
| Jun 11, 2025 | Intellia Therapeutics Inc. | Grant or award | +8,000 | — | — |
| May 15, 2025 | Cytokinetics Incorporated | Open-market sale | −1,454 | $29.73 | $43,227 |
| May 14, 2025 | Cytokinetics Incorporated | Grant or award | +7,333 | — | — |
| Apr 29, 2025 | Intellia Therapeutics Inc. | Open-market sale | −265 | $8.50 | $2,253 |
| Jan 29, 2025 | Intellia Therapeutics Inc. | Open-market sale | −265 | $9.97 | $2,642 |
| Jun 13, 2024 | Veracyte Inc. | Grant or award | +11,473 | — | — |
| Jun 12, 2024 | Intellia Therapeutics Inc. | Grant or award | +7,737 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.